Skip to content

Advertisement

Demyelinating diseases

Section edited by Francesco Patti and Tjalf Ziemssen

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Page 5 of 12
  1. Content type: Study protocol

    Multiple sclerosis (MS) is an incurable, unpredictable but typically progressive neurological condition. It is the most common cause of neurological disability in young adults. Within 15 years of diagnosis, ap...

    Authors: J. A. Freeman, W. Hendrie, S. Creanor, L. Jarrett, A. Barton, C. Green, J. Marsden, E. Rogers and J. Zajicek

    Citation: BMC Neurology 2016 16:62

    Published on:

  2. Content type: Study protocol

    The management of multiple sclerosis (MS) is rapidly changing by the introduction of new and more effective disease-modifying agents. The importance of risk stratification was confirmed by results on disease p...

    Authors: Gustavo Saposnik, Angel Perez Sempere, Roula Raptis, Daniel Prefasi, Daniel Selchen and Jorge Maurino

    Citation: BMC Neurology 2016 16:58

    Published on:

  3. Content type: Research article

    Reversible splenial lesion syndrome (RESLES) is a disorder radiologically characterized by reversible lesion in the splenium of the corpus callosum (SCC). Most of patients with RESLES associated with encephali...

    Authors: Yuanzhao Zhu, Junjun Zheng, Ling Zhang, Zhenguo Zeng, Min Zhu, Xiaobin Li, Xiaoliang Lou, Hui Wan and Daojun Hong

    Citation: BMC Neurology 2016 16:49

    Published on:

  4. Content type: Review

    Leakage of the blood–brain barrier (BBB) is a common pathological feature in multiple sclerosis (MS). Following a breach of the BBB, albumin, the most abundant protein in plasma, gains access to CNS tissue whe...

    Authors: Steven M. LeVine

    Citation: BMC Neurology 2016 16:47

    Published on:

  5. Content type: Study protocol

    Alemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In previous phase II and III clinical trials, alemtuzumab has proven superior efficacy to subcut...

    Authors: Tobias Ruck, Ali Maisam Afzali, Karl-Friedrich Lukat, Maria Eveslage, Catharina C. Gross, Steffen Pfeuffer, Stefan Bittner, Luisa Klotz, Nico Melzer, Heinz Wiendl and Sven G. Meuth

    Citation: BMC Neurology 2016 16:34

    Published on:

  6. Content type: Research article

    There is limited knowledge regarding how depressive symptoms and a cluster of specific mood symptoms in people with multiple sclerosis (MS) vary over time and how they are influenced by contributing factors. T...

    Authors: Sverker Johansson, Kristina Gottberg, Marie Kierkegaard and Charlotte Ytterberg

    Citation: BMC Neurology 2016 16:32

    Published on:

  7. Content type: Research article

    People with multiple sclerosis (MS) are increasingly using the Internet in the daily management of their condition. They search for high-quality information in plain language, from independent sources, based o...

    Authors: Cinzia Colombo, Graziella Filippini, Anneliese Synnot, Sophie Hill, Roberta Guglielmino, Silvia Traversa, Paolo Confalonieri, Paola Mosconi and Irene Tramacere

    Citation: BMC Neurology 2016 16:30

    Published on:

  8. Content type: Case report

    Leukoencephalopathy with calcifications and cysts (LCC or Labrune disease) is a relatively recently defined and exceptionally rare disease in which parenchymal cysts and calcifications within a widespread leuk...

    Authors: C. Stephani, S. Pfeifenbring, A. Mohr and C. Stadelmann

    Citation: BMC Neurology 2016 16:19

    Published on:

  9. Content type: Study protocol

    Multiple Sclerosis has a great impact on psychological functioning of patients and can be associated with various mental health disorders and symptoms. The most prevalent one is depression, which ranges from 1...

    Authors: Sara Carletto, Martina Borghi, Diana Francone, Francesco Scavelli, Gabriella Bertino, Marco Cavallo, Simona Malucchi, Antonio Bertolotto, Francesco Oliva and Luca Ostacoli

    Citation: BMC Neurology 2016 16:7

    Published on:

  10. Content type: Case report

    The evidence on the use of the oral dimethyl-fumarate after the discontinuation of treatment with natalizumab in people with Multiple Sclerosis is still little. Natalizumab discontinuation may induce the recur...

    Authors: Francesco Patti, Carmela Leone and Mario Zappia

    Citation: BMC Neurology 2015 15:252

    Published on:

  11. Content type: Research article

    Cognitive deficits are common in multiple sclerosis (MS) and require continuous monitoring. In routine examinations, screening instruments such as the Brief Repeatable Battery (BRB) may serve this purpose. It ...

    Authors: Sascha Hansen, Jana Muenssinger, Simona Kronhofmann, Stefan Lautenbacher, Patrick Oschmann and Philipp M Keune

    Citation: BMC Neurology 2015 15:246

    Published on:

  12. Content type: Research article

    Positron emission tomography (PET) images with amyloid tracers show normal uptake in healthy white matter, which suggests that amyloid tracers are potentially useful for studying such white matter diseases as ...

    Authors: Jordi A. Matías-Guiu, María Nieves Cabrera-Martín, Jorge Matías-Guiu, Celia Oreja-Guevara, Cristina Riola-Parada, Teresa Moreno-Ramos, Juan Arrazola and José Luis Carreras

    Citation: BMC Neurology 2015 15:243

    Published on:

  13. Content type: Research article

    Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information reg...

    Authors: Michael Gurevich, Gadi Miron, Rina Zilkha Falb, David Magalashvili, Mark Dolev, Yael Stern and Anat Achiron

    Citation: BMC Neurology 2015 15:240

    Published on:

  14. Content type: Research article

    We aimed to determine the association of clinical and routine cerebrospinal fluid biochemical markers (total protein, IgG index and oligoclonal bands) with disability in multiple sclerosis and whether these bi...

    Authors: Madlyne Becker, Clotilde Latarche, Emilie Roman, Marc Debouverie, Catherine Malaplate-Armand and Francis Guillemin

    Citation: BMC Neurology 2015 15:79

    Published on:

  15. Content type: Research article

    Epidemiological studies describe a latitude gradient for increased MS prevalence and a preponderance of disease in Caucasian individuals. However, individuals from other ethnic backgrounds and low-risk regions...

    Authors: Richard S Nicholas, Vassiliki Kostadima, Maya Hanspal, Benjamin R Wakerley, Ruhena Sergeant, Saskia Decuypere, Omar Malik, Rosemary J Boyton and Daniel M Altmann

    Citation: BMC Neurology 2015 15:72

    Published on:

Page 5 of 12

2016 Journal Metrics

Advertisement